Lilly Ventures is the venture capital arm of Eli Lilly and Company responsible for life science investing in North America and Europe. Our primary goal is to facilitate the success of companies in our areas of focus through early to expansion stage investments and value-adding resources.
Lilly Ventures currently has $200 million under management and focuses on three major areas of interest.
Current Team (4)Update
|Aug 1, 2016||Boston Tech Flash - Milpitas colon disease drug developer sets IPO targets to raise up to $87.2M|
|Jul 11, 2016||Boston Tech Flash - Milpitas colon disease drug developer hopes to raise up to $75M in IPO|
|Apr 11, 2016||Xconomy - Viamet Revisits IPO Plans, This Time With More Data|
|Mar 28, 2016||Venture Capital Database - Airbnb dissed by Four Seasons|
|Mar 25, 2016||Venture Capital Database - Corporate Deal Activity In Cancer Therapeutics Startups Nearly Doubles In 2015|
|Mar 15, 2016||Venture Capital Database - Attacking The Big C: Funding To Cancer Therapeutics Jumps To $2.8B In 2015|
|Jan 28, 2016||PE HUB - VC-backed Surface Oncology appoints chief scientific officer|
|Jan 28, 2016||Business Wire - Vito Palombella, PhD Joins Surface Oncology as Chief Scientific Officer|
115 W. Washington Street
Suite 1680 - South
Indianapolis, IN 46204